8-K: Varex Imaging Reports Mixed Q4 Results, Revenue at High End of Guidance

Varex Imaging Corporation announced its fourth quarter and full fiscal year 2024 results, with revenue at the high end of guidance but a year-over-year decrease in both revenue and earnings.

Summary

• Varex Imaging Corporation reported its unaudited financial results for the fourth quarter and full fiscal year 2024.
• Fourth quarter revenue reached $206 million, which was at the high end of the company's guidance range.
• However, this represents a 10% decrease in revenue compared to the same quarter last year.
• The medical segment saw a 12% year-over-year revenue decrease, while the industrial segment declined by 4%.
• Non-GAAP gross margin was 33%, down from 36% in the prior year's fourth quarter.
• Non-GAAP earnings per share decreased to $0.19 from $0.45 in the same period last year.
• For the full fiscal year, revenue totaled $811 million.
• The company ended the year with $213 million in cash and marketable securities.
• Cash flow from operations was $26 million for the quarter and $47 million for the full year.
• Varex is guiding for first quarter fiscal year 2025 revenue between $195 million and $215 million, with non-GAAP net earnings per diluted share between -$0.05 and $0.10.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the year-over-year revenue and earnings declines, despite the revenue being at the high end of guidance. The forward guidance also indicates a potential loss in the next quarter.

Positives

• Fourth quarter revenue met the high end of the company's guidance.
• The company has a strong cash position with $213 million in cash and marketable securities.
• Varex is making progress in developing and commercializing innovative technologies.
• The company is expanding into the growing cargo systems vertical.

Negatives

• Varex experienced a 10% year-over-year decrease in revenue for the fourth quarter.
• The medical segment saw a 12% year-over-year revenue decline.
• Non-GAAP gross margin decreased from 36% to 33% year-over-year.
• Non-GAAP earnings per share decreased from $0.45 to $0.19 year-over-year.
• The company is forecasting a potential loss in the first quarter of fiscal year 2025.

Risks

• The company faces risks related to reliance on a limited number of OEM customers.
• Varex is exposed to competition and pricing pressures.
• The company is subject to economic instability and changing political environments.
• Supply chain disruptions could impact operations.
• There are risks associated with maintaining and defending intellectual property rights.
• The company is exposed to potential disruptions of critical information systems and security breaches.
• Non-compliance with product-related regulations and delays in obtaining regulatory clearances could impact the business.
• Limitations imposed by debt financing agreements could restrict operations.

Future Outlook

Varex expects first quarter fiscal year 2025 revenue to be between $195 million and $215 million, with non-GAAP net earnings per diluted share between -$0.05 and $0.10.

Management Comments

• Sunny Sanyal, Chief Executive Officer, stated, 'Revenue of $206 million in the fourth quarter of fiscal year 2024 was at the high-end of our guidance range, driven by strength in our Industrial segment.'
• Sunny Sanyal added, 'Cash generation in the quarter was solid, ending the fiscal year with $213 million of cash and marketable securities on the balance sheet.'
• Sanyal also noted, 'Fiscal 2024 was a year of promising technological achievements. We made substantial progress in advancing innovative technologies like photon counting and nanotubes into applications development and commercialization phases.'

Industry Context

The results reflect a mixed performance in the medical and industrial imaging sectors, with the medical segment experiencing a more significant decline. The company's focus on new technologies and expansion into cargo systems indicates a strategic shift to address market changes and growth opportunities.

Comparison to Industry Standards

• Varex's revenue decline of 10% year-over-year in Q4 contrasts with some competitors in the medical imaging space who have shown more stable or positive growth, such as Siemens Healthineers who have reported growth in their imaging business.
• The decrease in non-GAAP gross margin from 36% to 33% suggests potential pricing pressures or increased costs, which is a concern compared to companies like Canon Medical Systems who have maintained higher margins.
• The company's focus on photon counting and nanotubes aligns with industry trends towards advanced imaging technologies, similar to initiatives by Philips Healthcare.
• Varex's expansion into the cargo systems vertical is a strategic move to diversify revenue streams, similar to how companies like Smiths Detection have expanded their security imaging solutions.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and earnings.
• Employees may be impacted by potential cost-cutting measures.
• Customers may be affected by changes in product offerings or pricing.
• Suppliers may experience changes in demand for their products.
• Creditors may be concerned about the company's financial performance.

Next Steps

• Varex will conduct an earnings conference call on November 19, 2024, at 3:00 p.m. Mountain Time.
• The company will continue to advance innovative technologies and expand into new markets.

Key Dates

Keywords

Varex Imaging, X-ray imaging, medical imaging, industrial imaging, financial results, revenue, earnings, gross margin, photon counting, nanotubes, cargo systems